Vivere Oncotherapies

Vivere Oncotherapies is a San Diego-based biotechnology company dedicated to developing next-generation small molecule inhibitors for oncology. The company's primary focus is on targeting integrins, specifically alpha-v beta-3 and alpha-v beta-5, which are overexpressed in various aggressive cancers. These targets contribute significantly to tumor growth, angiogenesis, and therapeutic resistance. Vivere's lead candidate, VIV-201, is designed to modulate the tumor microenvironment to enhance therapeutic efficacy. The company aims to address high unmet needs in indications such as glioblastoma and pancreatic cancer. Founded by renowned researcher Dr. David Cheresh, the company leverages deep expertise in integrin biology to advance its pipeline.